Indian Journal of Orthopaedics
https://doi.org/10.1007/s43465-024-01221-4

EDITORIAL

Barriers and Solutions Towards Integrating Orthobiologics into Clinical Orthopaedic Practice

Madhan Jeyaraman[1] · **Sathish Muthu**[2] · **S. S. Amarnath**[3]

Introduction

In the rapidly evolving field of orthopaedics, orthobiologics have emerged as a beacon of hope, promising to transform the way we approach musculoskeletal injuries and degenerative diseases. Orthobiologics, encompassing treatments derived from natural substances such as cells, tissues, and blood components, are revolutionizing patient care by enhancing the body's natural healing processes. These biologically derived materials are revolutionizing how we treat conditions traditionally managed with surgical interventions or long-term pharmacotherapy. The use of orthobiologics has expanded rapidly, moving from experimental therapies to becoming an integral part of the treatment arsenal for a variety of conditions, such as osteoarthritis, tendon injuries, and spinal disorders [1, 2]. From bone fractures to chronic joint pain, these biologics offer a novel approach to treating conditions that traditionally require invasive surgeries and long recovery periods. As we stand on the brink of a new era in medical science, the integration of orthobiologics into everyday clinical practice is poised to redefine patient outcomes and healthcare delivery.

Originating from advancements in regenerative medicine, orthobiologics harness the power of biological substances to promote repair and regeneration in damaged tissues. Treatments such as platelet-rich plasma (PRP), bone morphogenetic proteins (BMPs), and stem cell therapies are at the forefront of this transformation, showing promising results in clinical trials and gaining acceptance in orthopaedic practices worldwide [3]. As these therapies continue to evolve, their potential to improve patient outcomes and reduce recovery times has spurred significant interest within the medical community. Despite their growing acceptance, the systematic integration of orthobiologics into routine clinical practice remains a challenge. This is due in part to the need for standardized protocols and comprehensive clinical trials to establish efficacy and safety across diverse patient populations. Moreover, regulatory hurdles and economic considerations often complicate their adoption. Nevertheless, the potential benefits—ranging from faster recovery times to reduced need for surgical interventions—underscore the urgent need to incorporate these therapies into standard orthopaedic care. This editorial explores the challenges in the integration of orthobiologics in daily clinical practice and advocates strategic measures to overcome them.

Challenges and Barriers

Integrating orthobiologics into routine orthopaedic practice presents several challenges, from regulatory and economic issues to scepticism within the medical community. Addressing these barriers is crucial for the widespread adoption and success of these innovative therapies.

Regulatory Hurdles

The use of orthobiologics is subject to stringent regulatory scrutiny, primarily to ensure their safety and efficacy. In the USA, the FDA classifies orthobiologics based on their level of manipulation and intended use, ranging from minimally manipulated products like PRP to more complex therapies such as stem cell treatments [4]. Each category faces

✉ Madhan Jeyaraman
madhanjeyaraman@gmail.com

Sathish Muthu
drsathishmuthu@gmail.com

S. S. Amarnath
bonejointsurgeon@yahoo.co.in

[1] Department of Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Chennai, Tamil Nadu, India

[2] Department of Orthopaedics, Government Karur Medical College, Karur, Tamil Nadu, India

[3] Trauma and Orthopedic Surgeon, Trinity Central Hospital, Bangalore, India

Published online: 11 July 2024

different regulatory pathways, with more complex products requiring extensive clinical trials and detailed safety data before receiving approval. Internationally, the standards for approving and regulating orthobiologics vary significantly, creating additional complexities for global adoption [5]. Countries like Japan and South Korea have developed more streamlined pathways for regenerative therapies, while others maintain stringent regulations that can delay clinical availability [6].

Economic and Accessibility Issues

The economic implications of orthobiologics pose significant barriers to their widespread use. These therapies often come with high costs due to the advanced technology and processes involved in their preparation and administration. Insurance coverage for orthobiologics varies, with many providers considering them experimental or investigational, thereby limiting reimbursement and making them less accessible to patients. This issue is compounded in different healthcare settings, especially in low-resource environments where the availability of sophisticated treatments like BMAC or stem cell therapies is limited [6]. The high cost and lack of widespread insurance coverage hinder the broader adoption of orthobiologics, potentially exacerbating healthcare disparities.

Clinical Adoption and Scepticism

Despite the promising potential of orthobiologics, their adoption within the medical community is met with cautious optimism [7]. Concerns about inconsistent clinical outcomes and the variability in patient responses contribute to scepticism among practitioners. The lack of large-scale, long-term clinical data further complicates the acceptance of these therapies as standard care. Many clinicians demand more rigorous and extensive research to establish clear guidelines and protocols for their use. Additionally, the complexity and novelty of these treatments necessitate specialized training and expertise, which can be a deterrent for some practitioners considering integrating orthobiologics into their practice.

Strategies for Successful Integration of Orthobiologics

To effectively integrate orthobiologics into clinical practice, a comprehensive approach is necessary, encompassing education, research collaboration, and advocacy. The following strategies are critical to ensure that orthobiologics become a staple in orthopaedic care, offering significant benefits to patient outcomes as shown in Fig. 1.

Education and Training

Educating healthcare professionals about orthobiologics is paramount. Continuing medical education (CME) programmes and specialized training are essential to equip practitioners with the knowledge and skills needed to apply these therapies effectively. Training programmes should emphasize the latest research findings, techniques for cell manipulation that comply with regulatory standards, and the clinical applications of different orthobiologic products. Furthermore, postgraduate education should include modules on orthobiologics, encouraging upcoming healthcare professionals to incorporate these therapies into their practice from the onset.

Collaborative Research

Increased collaboration between researchers, clinicians, and industry partners is vital to advance the evidence base for orthobiologics and refine treatment protocols. Interdisciplinary research projects should be prioritized, particularly in areas where evidence is currently lacking. Obtaining institutional ethics committee (IEC) approval for both therapeutic and research practices is crucial to maintain ethical standards and enhance the credibility of findings. Registration of clinical trials involving orthobiologics with the Clinical Trials Registry of India (CTRI) or equivalent bodies in other countries ensures transparency and fosters trust in these therapies. Collaborative efforts should aim to generate robust, evidence-based data to compete with and potentially surpass traditional standards of care treatments.

Policy and Advocacy

Engagement with policymakers is essential to support the integration of orthobiologics into clinical practice. Advocacy should focus on establishing clear regulatory pathways that facilitate the safe and effective use of orthobiologics. This includes ensuring that cell manipulation practices adhere to national standards, such as those outlined by Indian regulatory bodies. Additionally, promoting insurance reimbursement policies for orthobiologics will make these therapies more accessible and reduce economic barriers for patients.

Promotion of orthobiologics can be achieved through various platforms:

- Conferences and workshops: organizing state, national, and international conferences dedicated to orthobiologics, including separate presentations and hands-on



Fig. 1 Barrier and solutions to the integration of orthobiologics in routine clinical orthopaedic practice

workshops, will raise awareness and foster knowledge sharing among practitioners.

- Case series and webinars: encouraging the publication of case series and conducting webinars on orthobiologic treatments will help disseminate practical insights and clinical experiences.
- Sensitization campaigns: initiatives to raise awareness and sensitize fellow orthopaedic surgeons about the potential of orthobiologics are necessary; these could include targeted education campaigns and integration into orthopaedic societies' agendas.

Advocacy efforts should also promote evidence-based practice, emphasizing studies and trials that focus on both clinical and functional outcomes rather than solely on subjective improvements. This approach ensures that the use of orthobiologics is grounded in rigorous scientific evidence, enhancing their acceptance and integration into mainstream orthopaedic care.

Future Directions

The field of orthobiologics is rapidly evolving, with several emerging technologies poised to transform orthopaedic care. Gene therapy stands at the forefront, offering the potential to enhance tissue regeneration by modifying gene expression in targeted cells. This could lead to more effective treatments for conditions such as osteoarthritis and tendon injuries by promoting the natural production of healing factors within the body. Personalized medicine is another promising trend, leveraging advancements in genomics and proteomics to tailor orthobiologic treatments to individual patients. This approach aims to optimize therapeutic outcomes by aligning treatments with each patient's unique genetic and molecular profile, potentially improving efficacy and reducing adverse effects. Next-generation biomaterials, including synthetic scaffolds and bioengineered tissues, are being developed to provide structural support and enhance the integration of orthobiologics with native tissues. These innovations could facilitate more effective and reliable tissue regeneration, especially in complex orthopaedic conditions requiring precise repair and reconstruction.

Future research in orthobiologics will likely focus on several key areas. Optimizing delivery methods for orthobiologic agents remains crucial, with efforts aimed at improving the targeting and sustained release of these therapies to enhance their effectiveness. Understanding long-term outcomes is also essential, as there is a need for extensive studies to evaluate the durability and safety of orthobiologic treatments over time. Exploring novel applications of

orthobiologics, such as their use in preventing degeneration or treating early-stage musculoskeletal conditions, represents another critical research frontier. This could expand the therapeutic potential of orthobiologics beyond their current uses, providing new avenues for early intervention and prevention in orthopaedic care.

Looking ahead, orthobiologics have the potential to revolutionize orthopaedic practice and patient care profoundly. As these therapies continue to advance, they promise to deliver more personalized, effective, and less invasive treatments for a broad range of musculoskeletal disorders. The integration of orthobiologics into standard clinical practice could lead to significant improvements in patient outcomes, reducing the reliance on surgical interventions and enhancing the quality of life for countless individuals. Embracing these innovations will undoubtedly drive the future of orthopaedics, making it a more regenerative and patient-centred field.

Conclusion

The integration of orthobiologics into clinical practice heralds a transformative shift in orthopaedic care. These biologically derived therapies offer promising alternatives to traditional surgical and pharmacological treatments, providing pathways to more effective, less invasive care in appropriately chosen patients. As the field advances, the ongoing research and development of technologies such as gene therapy and personalized medicine will further enhance the capabilities and applications of orthobiologics. Addressing current challenges that range from regulatory hurdles to economic and clinical adoption issues, collaborative efforts and targeted advocacy are crucial. The future of orthopaedics lies in embracing these innovations, ensuring that orthobiologics become a cornerstone of patient-centred, regenerative treatment modality. This paradigm shift not only promises to improve patient outcomes and reduce recovery times, but also redefines the standard of care for musculoskeletal disorders, fostering a new era in medical science.

Data availability Data is contained within the manuscript.

Declarations

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval This article does not contain any studies with human or animal subjects performed by the any of the authors.

Informed consent For this type of study informed consent is not required.

References

1. Jeyaraman, M., Muthu, S., Nischith, D. S., Jeyaraman, N., Nallakumarasamy, A., & Khanna, M. (2022). PRISMA-compliant meta-analysis of randomized controlled trials on osteoarthritis of knee managed with allogeneic vs autologous MSCs: Efficacy and safety analysis. *Indian Journal of Orthopaedics, 56*(12), 2042–2059. https://doi.org/10.1007/s43465-022-00751-z
2. Arthur Vithran, D. T., Xie, W., Opoku, M., Essien, A. E., He, M., & Li, Y. (2023). The efficacy of platelet-rich plasma injection therapy in the treatment of patients with achilles tendinopathy: A systematic review and meta-analysis. *Journal of Clinical Medicine, 12*(3), 995. https://doi.org/10.3390/jcm12030995
3. Cheung, E. C., Hodax, J. D., Hsu, W. K., Williams, S. K., Smith, H. E., Lansdown, D. A., et al. (2020). Platelet-rich plasma, bone morphogenetic protein, and stem cell therapies. *Instructional Course Lectures, 69*, 273–288.
4. Knoepfler, P. S. (2015). From bench to FDA to bedside: US regulatory trends for new stem cell therapies. *Advanced Drug Delivery Reviews, 82–83*, 192–196. https://doi.org/10.1016/j.addr.2014.12.001
5. Muthu, S., Jeyaraman, M., Kotner, M. B., Jeyaraman, N., Rajendran, R. L., Sharma, S., et al. (2022). Evolution of mesenchymal stem cell therapy as an advanced therapeutic medicinal product (ATMP)-an indian perspective. *Bioengineering (Basel, Switzerland), 9*(3), 111. https://doi.org/10.3390/bioengineering9030111
6. Lee, S., & Lee, J. H. (2023). Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU. *Frontiers in Public Health*. https://doi.org/10.3389/fpubh.2023.1109873
7. Guleria, I., de Los Angeles Muñiz, M., Wilgo, M., Bapat, A., Cui, W., Hsu, Y.-M.S., et al. (2022). How do I: Evaluate the safety and legitimacy of unproven cellular therapies? *Transfusion, 62*(3), 518–532. https://doi.org/10.1111/trf.16814